期刊文献+

沙格列汀联合甘精胰岛素治疗2型糖尿病的疗效及对血糖波动的影响 被引量:5

下载PDF
导出
摘要 目的研究沙格列汀联合甘精胰岛素治疗2型糖尿病的疗效及对血糖波动控制效果。方法 62例2型糖尿病患者,随机分为治疗组和对照组,各31例。对照组给予格列美脲联合甘精胰岛素治疗,治疗组给予沙格列汀联合甘精胰岛素治疗,比较两组患者的体质量指数(BMI)、空腹血糖(FPG)、收缩压(SBP)、平均血糖波动幅度(MAGE)、血糖平均绝对差(MODD)、高血糖曲线下面积(AUC)、低血糖AUC、血糖波动次数(NGE)。结果治疗组患者BMI为(22.13±2.08)kg/m^2、FPG为(6.25±1.51)mmol/L、SBP为(125.12±9.87)mm Hg(1 mm Hg=0.133 kPa);对照组患者BMI为(24.27±2.43)kg/m^2、FPG为(6.35±1.48)mmol/L、SBP为(128.25±10.34)mm Hg;治疗组BMI低于对照组差异有统计学意义(P<0.05);两组FPG、SBP比较差异无统计学意义(P>0.05)。治疗组高血糖AUC、低血糖AUC均低于对照组,差异有统计学意义(P<0.05);两组MAGE、MODD及NGE比较差异无统计学意义(P>0.05)。结论沙格列汀联合甘精胰岛素对2型糖尿病患者的血糖控制效果更明显,可有效降低血糖,值得在临上推广。
作者 丛令波
出处 《中国现代药物应用》 2019年第4期128-129,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献9

二级参考文献60

  • 1Ceriello A, Ihnat MA. Glycaemic variability: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med, 2010,27 : 862-867.
  • 2Hsu CW. Glycemic control in critically ill patients. World J Crit Care Med,2012,1:31 39.
  • 3Egi M,Bellomo R,Stachowski E,et al. Variability of blood glu- cose concentration and short-term mortality in critically ill pa- tients. Anesthesiology, 2006,105 : 244 252.
  • 4Hirsch IB, Brownlee M. Should minimal blood glucose variabili ty become the gold standard control? J Diabetes Complica tions, 2005,19 : 178 181.
  • 5Vilsboll T, Rosenstock J, Yki-Jfirvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab,2010,12:167-177.
  • 6He YL, Foteinos G, Neelakantham S, et al. Differential effects of vildagliptin and glimepiride onglucose fluctuations in patients with type 2 diabetesmellitus assessed using continuous glucose monitoring. Diabetes Obes Metab, 2013,15 : 1111-1119.
  • 7Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26 : sulpho- nylurea failure in non-insulin-dependent diabetic patients over six years[J]. Diabetes Med, 1998,15(4) : 297-303.
  • 8Herman GA,Bergrnan A,Stevens C,et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes [J]. J Clin Endocrinol Metab, 2006,91 ( 11 ) : 4612-4619.
  • 9Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancent, 2006, 368 (9548): 1696-1705.
  • 10Wang Q, Li L, Xu E, et al. Glucagon like peptide-1 regulates proliferation and apoptosis visa activation protein kinase B in pancreatic INS-lbeta cells [J]. Diabetologia, 2004, 47 (3): 478-487.

共引文献138

同被引文献50

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部